Skip to main content

All Weight Gain is Not the Same: Fatty Liver Disease in People with HIV

AAHIVM Course Banner
1.5 CEUs
All Weight Gain is Not the Same:
Fatty Liver Disease in People with HIV

Module DescriptionA discussion of the prevalence of fatty liver disease and non-alcoholic steatohepatitis (NASH) among PWH and risk factors including per/epicardial fat, skeletal muscle fat accumulation and the progression of fatty liver disease to NASH, fibrosis and liver failure in PWH.

Credit Dates12/09/21 – 12/09/22

Jointly provided by Postgraduate Institute for Medicine and American Academy of HIV Medicine.

This activity is supported by an independent education grant from Theratechnologies.
Learning Objectives
  • Identify factors contributing to the accumulation of visceral adipose tissue (VAT) among PWH
  • Describe the cardiometabolic disease risks associated with VAT in PWH
  • Describe the prevalence of excess VAT in PWH and methods of measurement
  • Describe options for clinical management of VAT

Target Audience
This activity has been designed to meet the educational needs of physicians, physician assistants, nurse practitioners, pharmacists, and registered nurses; other healthcare providers, such as nutritionists, social workers, and case managers are also encouraged to attend.

John R. Koethe MD, MSCI, FIDSA
Associate Professor of Medicine
Division of Infectious Diseases
Vanderbilt University Medical Center

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity.

In order to obtain your CE certificate, please follow the steps below at the conclusion of the activity:
  • Go to
  • Login or Create a New Account (will take less than 1 minute)
    1. If you receive a message when creating a new account that “the email you entered is already in use”, please click the Forgot my Username or Password link to have your Username and Password sent to you via email
    2. After logging in, you may be asked to verify/update your information; after doing so, click Save at the bottom of the page
  • Type in 16804 at the top of the page, “Find Post-Test/Evaluation by Course”, and click enter
  • Click on the activity title when it appears
  • Choose the type of credit you desire
  • Complete the Post-test with a passing score of 75% or better
  • Complete the online Evaluation
  • Receive an immediate CE Certificate to download and/or print for your files

If you have questions regarding the certification of this activity, please contact PIM via email at or visit

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and the American Academy of HIV Medicine. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact house (0.5 APRN credit hours).

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hour(s) (0.5 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number JA4008162-9999-21-379-H02-P)
Type of Activity: Knowledge

Disclosure of Conflict of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. The existence or absence of COI for everyone in a position to control educational content will be disclosed to participants prior to the start of each activity.

Dr. Koethe has served as a consultant to Merck & Co., Gilead Sciences, ViiV Healthcare, Janssen Pharmaceuticals and Theratechnologies, and received research support from Merck & Co. and Gilead Sciences.

Planners and Managers
The planners and their spouses/partners wish to disclose they have no financial interests or other relationships with any ACCME-defined ineligible companies.

Media: Internet

Computer System Requirements: requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.